Monday, January 10, 2011

Myelin Repair Foundation Identifies 40+ Possible Repurposing Opportunities for Next Generation Multiple Sclerosis Therapy | Business Wire
The analysis of publicly available data was conducted by the MRF Drug Discovery Advisory Board of outside biopharmaceutical experts to aid the Foundation in prioritizing the overwhelming number of targets generated in its funded laboratories at Stanford University, the University of Chicago, Northwestern University, Case Western Reserve University, University of California-San Francisco and the University of Melbourne, Victoria, Australia.
“From day one, we set out to find ways to accelerate the time to market for this next generation MS therapy. This analysis gives us critical information to engage  read more

Bookmark and Share
Enhanced by Zemanta